{"title":"错误部","authors":"","doi":"10.1016/s0140-6736(24)02478-4","DOIUrl":null,"url":null,"abstract":"<em>Park S-J, Ahn J-M, Kang D-Y, et al. Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial</em>. Lancet <em>2024; <strong>403:</strong> 1753–65</em>—In table 2 of this Article, the proportion of patients in the optimal medical therapy group with target-vessel-related myocardial infarction at 4 years should have been 0·9%. This correction has been made to the online version as of Nov 14, 2024.","PeriodicalId":18014,"journal":{"name":"The Lancet","volume":"13 1","pages":""},"PeriodicalIF":109.0000,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Department of Error\",\"authors\":\"\",\"doi\":\"10.1016/s0140-6736(24)02478-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<em>Park S-J, Ahn J-M, Kang D-Y, et al. Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial</em>. Lancet <em>2024; <strong>403:</strong> 1753–65</em>—In table 2 of this Article, the proportion of patients in the optimal medical therapy group with target-vessel-related myocardial infarction at 4 years should have been 0·9%. This correction has been made to the online version as of Nov 14, 2024.\",\"PeriodicalId\":18014,\"journal\":{\"name\":\"The Lancet\",\"volume\":\"13 1\",\"pages\":\"\"},\"PeriodicalIF\":109.0000,\"publicationDate\":\"2024-11-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Lancet\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/s0140-6736(24)02478-4\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/s0140-6736(24)02478-4","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
摘要
Park S-J、Ahn J-M、Kang D-Y等:预防性经皮冠状动脉介入治疗与单纯最佳药物治疗治疗易损冠状动脉粥样硬化斑块(PREVENT):一项多中心、开放标签、随机对照试验。Lancet 2024; 403: 1753-65-在本文表2中,最佳药物治疗组中4年后发生靶血管相关心肌梗死的患者比例应为0-9%。截至2024年11月14日的在线版本已作此更正。
Park S-J, Ahn J-M, Kang D-Y, et al. Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial. Lancet 2024; 403: 1753–65—In table 2 of this Article, the proportion of patients in the optimal medical therapy group with target-vessel-related myocardial infarction at 4 years should have been 0·9%. This correction has been made to the online version as of Nov 14, 2024.
期刊介绍:
The Lancet is a world-leading source of clinical, public health, and global health knowledge. It was founded in 1823 by Thomas Wakley and has been an independent, international weekly general medical journal since then. The journal has an Impact Factor of 168.9, ranking first among 167 general and internal medicine journals globally. It also has a Scopus CiteScore of 133·2, ranking it second among 830 general medicine journals. The Lancet's mission is to make science widely available to serve and transform society, positively impacting people's lives. Throughout its history, The Lancet has been dedicated to addressing urgent topics, initiating debate, providing context for scientific research, and influencing decision makers worldwide.